Management of ST-Elevation Myocardial Infarction (STEMI)

Immediate Reperfusion Strategy

• The European Society of Cardiology recommends primary percutaneous coronary intervention (PCI) as the definitive reperfusion strategy, to be performed within 90-120 minutes of first medical contact, for all STEMI patients with symptoms less than 12 hours duration, with Class I, Level A evidence 1, 2
• If primary PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolytic therapy should be initiated immediately using a fibrin-specific agent, preferably in the pre-hospital setting, according to the European Society of Cardiology 1, 2

Antithrombotic Regimen

• The European Society of Cardiology recommends aspirin 150-325 mg oral or IV (if unable to swallow) should be administered immediately, with Class I, Level B recommendation 1, 2
• A potent P2Y12 inhibitor, such as prasugrel or ticagrelor, must be given before or at the time of PCI and maintained for 12 months, with Class I, Level A evidence, according to the European Society of Cardiology 1, 2, 3
• Unfractionated heparin as weight-adjusted IV bolus followed by infusion is recommended for primary PCI, according to the European Society of Cardiology 1, 2, 4

Symptom Management

• Morphine 4-8 mg IV with additional 2 mg doses at 5-15 minute intervals should be administered for pain control and anxiety reduction, according to the European Society of Cardiology 4
• Routine oxygen is not recommended unless SaO2 is <90%, with Class III, Level B evidence, according to the European Society of Cardiology 3

Post-Reperfusion Management

• All patients receiving fibrinolysis must be transferred to a PCI-capable center immediately after fibrinolysis, with Class I, Level A evidence, according to the European Society of Cardiology 1, 2
• Emergency angiography and PCI immediately if heart failure/shock develops, with Class I, Level A evidence, according to the European Society of Cardiology 1, 2

Long-Term Antithrombotic Strategy

• Dual antiplatelet therapy (DAPT) with aspirin 75-100 mg plus ticagrelor or prasugrel (or clopidogrel if unavailable/contraindicated) should be continued for 12 months, unless excessive bleeding risk exists, with Class I, Level A evidence, according to the European Society of Cardiology 1, 2, 3
• A proton pump inhibitor (PPI) in combination with DAPT is recommended for patients at high risk of gastrointestinal bleeding, with Class I, Level B evidence, according to the European Society of Cardiology 1, 2

Management of ST Elevation Myocardial Infarction Without Chest Pain

Initial Recognition and Triage

• The European Society of Cardiology recommends treating ST elevation without chest pain as a true STEMI requiring immediate reperfusion therapy, as the absence of chest pain does not change the urgency or management approach, though it significantly increases mortality risk and delays in care 5
• ST elevation on ECG signifies complete coronary artery occlusion requiring immediate reperfusion, regardless of symptom presentation, according to the European Heart Journal 6, 5
• Persistent ST elevation (>20 minutes) is equivalent to STEMI pathway activation, as stated by the European Heart Journal 5, 7

Immediate Management Algorithm

• The American Heart Association recommends placing patients on continuous cardiac monitoring, as stated in the journal Circulation 8
• Obtain 12-lead ECG within 10 minutes of presentation, as recommended by the American Heart Association in the journal Circulation 9
• Do not delay reperfusion therapy based on absence of chest pain, as advised by the European Heart Journal 5

Reperfusion Strategy Decision

• The European Society of Cardiology recommends performing primary PCI within 90-120 minutes of first medical contact if PCI-capable facility is available within this timeframe, regardless of symptom presentation 5

Post-Reperfusion Care

• The American Heart Association recommends continuous ECG monitoring for arrhythmias, as stated in the journal Circulation 8
• Monitor for recurrent ischemia (ECG changes, symptom recurrence), as recommended by the European Heart Journal 6, 5
• The American College of Cardiology recommends beta-blocker, ACE inhibitor, statin per standard post-MI protocols, as stated in the journal Circulation 8

Primary Percutaneous Coronary Intervention (PCI) as the Definitive Treatment for STEMI

Indications and Guideline Recommendations

• Primary PCI performed within 90–120 minutes of first medical contact is the definitive reperfusion strategy for acute anterior STEMI in adult patients. 10
• The European Society of Cardiology assigns a Class I, Level A recommendation to primary PCI for all STEMI patients presenting ≤12 hours from symptom onset. 10
• Primary PCI reduces mortality, reinfarction, and stroke compared with fibrinolytic therapy when delivered by experienced operators in a timely fashion. 10
• When PCI can be achieved ≤120 minutes after STEMI diagnosis, it remains the preferred strategy even though reperfusion time is less critical than for fibrinolysis. 10
• Fibrinolytic therapy is indicated only when primary PCI cannot be performed within 120 minutes of STEMI diagnosis. 10

Procedural Details

• Door‑to‑balloon target: < 90 minutes for patients presenting ≤2 hours from symptom onset. (Class I) [10][11]
• Vascular access: Radial approach is preferred over femoral access. (Class I) 10
• Stent choice: Drug‑eluting stents are the standard of care for primary PCI. (Class I) [10][12]
• Lesion focus: Only the infarct‑related artery should be treated during the acute PCI procedure. (Class I) 13

Medication Protocols Prior to PCI

• Aspirin: 150–325 mg oral or IV administered immediately on presentation. (Class I) – citation omitted because not referenced.
• Potent P2Y12 inhibitor loading: Prasugrel 60 mg or ticagrelor 180 mg given before or at the time of PCI. (Class I) 10
• Unfractionated heparin: Weight‑adjusted IV bolus administered before PCI. (Class I) – citation omitted.
• Morphine: 4–8 mg IV for analgesia, repeat 2 mg doses every 5–15 minutes as needed. (Class I) 11

Contraindicated or Discouraged Practices

• Delaying PCI for troponin results is not recommended; an ECG diagnosis is sufficient to proceed. (Class I) 11
• Routine thrombus aspiration is contraindicated (Class III). 10
• Treating non‑culprit vessels during the index PCI is discouraged unless the patient is in cardiogenic shock. (Class III) 10
• NSAIDs for pain relief are prohibited because of pro‑thrombotic effects. (Class I) 11

Post‑PCI Monitoring

• Continuous cardiac monitoring for at least 24 hours is advised to detect arrhythmias. (Class I) 10

Fibrinolysis When Primary PCI Is Not Feasible

• If PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolysis becomes appropriate. (Class I) 10
• A fibrin‑specific agent (tenecteplase preferred over streptokinase) should be administered within 10 minutes of decision. (Class I) 10
• After successful fibrinolysis, coronary angiography should be performed within 24 hours. (Class I) 13

Management of Persistent ST‑Elevation After Antiplatelet Loading and Fibrinolysis

Definition and Clinical Significance

• Persistent ST‑segment elevation beyond 60–90 minutes after fibrinolytic administration indicates failed pharmacologic reperfusion and mandates immediate rescue intervention. This reflects ongoing coronary occlusion despite therapy. 14

Immediate Transfer and Rescue PCI

• All patients with failed reperfusion or re‑occlusion after fibrinolysis should be transferred without delay to a PCI‑capable center for urgent coronary angiography and rescue PCI. The ACC/AHA guidelines assign this a Class IIa recommendation, Level B evidence (reasonable with moderate‑quality data). [15][16]

Pharmacologic Strategies

Fibrinolytic Re‑administration

• Re‑administration of a fibrinolytic agent is not recommended as the primary strategy for persistent ST‑elevation. The REACT trial showed that a second fibrinolytic dose was inferior to rescue PCI and not superior to conservative therapy. 14
• A second dose of a non‑immunogenic fibrinolytic may be considered only as a last‑resort when rescue PCI is absolutely unavailable, the infarct is large, and bleeding risk is low. 14

Anticoagulation Support for PCI

• Unfractionated heparin (UFH) should be continued or initiated with weight‑adjusted dosing and additional boluses as needed to support the PCI procedure, taking into account any concurrent GP IIb/IIIa inhibitor use. [15][16]
• Fondaparinux must not be used as the sole anticoagulant during PCI because of a high risk of catheter thrombosis (Class III: Harm). [15][16]

P2Y12 Inhibitor Management

Avoidable Pitfalls

• Delaying mechanical reperfusion beyond 60–90 minutes after fibrinolysis worsens outcomes; immediate rescue PCI is essential. 14
• Additional fibrinolytic dosing increases bleeding risk (including intracranial hemorrhage) without improving reperfusion outcomes compared with rescue PCI. 14
• Premature prasugrel administration (within 24 h of fibrin‑specific fibrinolysis) raises bleeding risk and is contraindicated in patients with prior stroke or TIA (Class III: Harm). [15][16]

Post‑Rescue PCI Therapy

• Continue aspirin 81 mg daily (range 81–325 mg) indefinitely after rescue PCI. [15][16]
• Maintain a P2Y12 inhibitor for 12 months: clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily. [15][16]